FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.
What happened
FDA inspected Innocore Sales & Marketing's drug manufacturing facility in Woodstock, Ontario, Canada, from April 22 to 25, 2025, and found significant current good manufacturing practice (CGMP) violations for finished drugs. FDA said the company lacked adequate finished-product release testing, identity testing of incoming components at risk for diethylene glycol (DEG) and ethylene glycol (EG), an adequate stability program, and quality-unit oversight; it also noted similar observations in a June 2019 inspection. The company's May 16, 2025, response was inadequate, FDA said.
What FDA found
The company did not adequately test each finished drug batch before release for identity and strength of the active ingredient and for objectionable microorganisms.
21 CFR 211.165(a) and 211.165(b)The company did not perform an adequate identity test on each incoming lot of a component, including one at higher risk for diethylene glycol or ethylene glycol contamination.
21 CFR 211.84(d)(1)The company lacked adequate stability data and storage to show its drug products keep their quality through the labeled expiry in the marketed container.
21 CFR 211.166(a)The quality control unit did not ensure adequate cleaning and maintenance, batch records, and investigations with lasting corrective actions.
21 CFR 211.22; 21 CFR 211.67(a); 21 CFR 211.188; 21 CFR 211.192
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and detailed plans for laboratory testing, component testing, stability, and quality-unit oversight; it also asks for DEG/EG test results from retained samples within 30 calendar days.
Who should pay attention
- over-the-counter drug brands and retailers that use this contractor
- suppliers of high-risk drug components such as glycerin
- companies relying on supplier certificates of analysis for incoming ingredients
This is a summary. Read the original letter on fda.gov.